Ted Yanagihara, MD, PhD

Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma @JHepatology doi.org/10.1016/j.jhep… 👉Disappointing, we need to do better... @myESMO @EASLedu @ILCAnews

So thrilled to see our collaborative publication with @tedradonc, @ma5RN and many others now online in @JCO_ASCO These data from a large, multinational cohort provide further support for EBRT's role in the management of HCC. ascopubs.org/doi/10.1200/JC…

Congratulations @ma5RN @tedradonc @AndrewMMoon in this impressive work positioning EBRT as a key locoregional treatment in #HCC! Proud to have been part of this joint effort between @BCLC_gr and the radiation oncology community 🙌 #RadOnc

Major international IPD effort by @ma5RN @AndrewMMoon and @tedradonc crafting a great team to assess the survival of almost 5000 HCC patients treated with EBRT and stratified by BCLC stage. Best information available to consider EBRT in clinical practice pubmed.ncbi.nlm.nih.gov/42139645/

@drjamesgood redjournal.org/article/S0360-…

@tedradonc Link doesn’t seem to work

#radonc, what do you think the alpha/beta is for HCC? 6? 10? How about a/b>30! tinyurl.com/486t87ma But don't interpret this to mean HCC is highly radiosensitive (it's more intermediate). Authors make the case that this is partly due to an insensitivity to fractionation

@MuzamilArshad18 redjournal.org/article/S0360-…

@tedradonc Could you provide reference, link dosent work I think

Sorry for the link issue, it was passing through my library proxy. This should work: redjournal.org/article/S0360-…

Final print of BCLC 2025 available at authors.elsevier.com/c/1mZTWcOnAYVAl A team effort by BCLC members and external experts. Incorporation of CUSE concepts into the MTBoard allows personalised recommendations @hospitalclinic @idibaps @EASLnews @ILCAnews @AEEHLiver @ContraCancerEs

@BCLC_group BCLC 2025 update 🔝🔝 incorporates recent advances in the field of treatment recommendations for #HCC, such as #EBRT Amazing sessions and clinical scenarios discussion!!

BCLC 2025 update is live and introduces a new framework (CUSE) that aims to guide clinicians and patients through the many dilemmas encountered when making treatment decisions. Congrats to the @BCLC_group and thank you all, esp @ma5RN , for the opportunity to contribute!

@DrSpratticus @NicholasZaorsky @CWRUSOM @UHhospitals @RadOncUH @ASTRO_org Congrats, Nick. Well deserved!!

Incredibly proud of ⁦@NicholasZaorsky⁩ who was just promoted to be a Full Professor with Tenure at ⁦@CWRUSOM⁩ and ⁦@UHhospitals⁩. Congrats on all you have accomplished. You elevate ⁦@RadOncUH⁩ and our field. ⁦@ASTRO_org⁩

@toddscarbrough I don’t think most people will get it, but I chuckled

Radiation oncologists #radonc **do not** radiate tumors Unless it's some weird AI video, or if a rad onc could contract devil facial tumor disease, etc.

🤨5,000 patients later Roche scraps its TIGIT 👇oncologypipeline.com/apexonco/5000-…

More disappointing news in #HCC: Adjuvant pembrolizumab failed to beat surveillance in the global P3 #KEYNOTE-937 trial (NCT03867084). Merck disclosed the negative result quietly in an SEC filing. Not unexpected after #IMbrave050

@freddyeescorcia 🔥

Happy proofs day to those who celebrate… Details forthcoming! #radiopharmaceuticals #theranostics #hcc

Happening tomorrow! FREE #RSSwebinar "Celiac Plexus Radiosurgery: A New Treatment Modality for Pancreatic Cancer Pain" on Tues, 6/17 at noon ET! @LawrenceYaacov @banu_atalar @the_RSS

Great new @AmCollegeGastro Guideline Highlights summarizing some key points on diagnosis and management of focal liver lesions Guideline: journals.lww.com/ajg/fulltext/2…

Exciting to bring the tech to USA. I hope the lessons on proton are not repeated. Over 40,000 patients have been treated with carbon ion worldwide. Unclear what cancers this enhances your ability to treat. It is ok to bring new tech and do research with it and not claim it is better until proven to be. Keeps equipoise for RCTs. I truly hope this won’t be a way to attract patients to pay high out of pocket costs for a treatment without proven superiority….please don’t start advertising for things like prostate and breast cancer. Kudos for bringing it to USA!

🚨Study activated! NRG GI-011: Ph 3 RCT of Dose-Escalated RT in Locally Advanced Pancreas Cancer (LAP100) Here's a short (7 min) video. Please consider enrolling & reach out w any q's. Thanks to the NIH, NCI, @NRGonc for supporting our work! clinicaltrials.gov/study/NCT06958… 🙏🙏🙏